How follicular helper T cells (T FH cells) differentiate to regulate B cell immunity is critical for effective protein vaccination. Here we define three transcription factor T-bet-expressing antigen-specific effector helper T cell subsets with distinguishable function, migratory properties and developmental programming in vivo. Expression of the transcriptional repressor Blimp-1 distinguished T zone 'lymphoid' effector helper T cells (CD62L hi CCR7 hi ) from CXCR5 lo 'emigrant' effector helper T cells and CXCR5 hi 'resident' T FH cells expressing the transcriptional repressor Bcl-6 (CD62L lo CCR7 lo ). We then show by adoptive transfer and intact polyclonal responses that helper T cells with the highest specific binding of peptide-major histocompatibility complex class II and the most restricted T cell antigen receptor junctional diversity 'preferentially' developed into the antigen-specific effector T FH compartment. Our studies demonstrate a central function for differences in the binding strength of the T cell antigen receptor in the antigen-specific mechanisms that 'program' specialized effector T FH function in vivo.
Vaccination with protein induces high-affinity B cell memory for long-term protection against infectious disease. Antigen-specific helper T cells with many effector functions are the central cognate regulators of this B cell immune response in vivo 1, 2 . Follicular helper T cells (T FH cells) have emerged as another lineage of helper T cells functionally subspecialized to regulate many facets of the development of effector and memory B cells 3, 4 . Understanding the antigen-specific mechanisms that control the differentiation of effector T FH cells is critical for the design of future vaccines but remains poorly resolved in vivo.
The appropriate placement of antigen-specific T FH cells during immune responses is important for the cognate delivery of effector function to antigen-primed B cells 5, 6 . Loss of the chemokine receptor CCR7 and expression of the chemokine receptor CXCR5 relocate effector T FH cells to the B cell areas of secondary lymphoid tissue 7, 8 . In these locations, expression of the costimulatory molecules CD40L 9 , ICOS 10, 11 , PD-1 (ref. 12 ) and OX40 (ref. 13 ) helps modify antigenspecific contact with B cells expressing peptide-major histocompatibility complex (MHC) class II (pMHCII). The cytokines interleukin 4 (IL-4; A001262), IL-10 (ref. 6 ) and interferon-g (IFN-g) 12 can also serve an important regulatory function at this cognate interface to affect subsequent development and function of antigen-specific B cells. Early studies of the differentiation program of T FH cells indicated involvement of expression of the transcriptional repressor Bcl-6 (A000369) 13 , local lymphoid priming 14 , expression of the ICOS ligand on B cells, IL-6, IL-21 (A001258), the transcription factor STAT3 (ref. 15) , the strength of T cell antigen receptor (TCR) signaling through greater abundance of the Vav1 guanine nucleotide-exchange factor 16 and the duration of stable T cell-B cell contacts controlled by signaling lymphocytic activation molecule-associated proteins 17 . To delineate the cognate mechanisms of effector T FH differentiation, it remains necessary to define the dynamics of the development of antigen-specific effector T FH cells and distinguish those cells from the many other antigen-specific effector helper T cells that may arise after local protein vaccination.
The strength of TCR signaling affects lineage commitment during thymic development, and in the periphery, it is important for the establishment of selection thresholds for fitness and survival in vitro 18, 19 and clonal expansion after antigen priming in vivo [20] [21] [22] . It has also been shown that the strength of the pMHCII signal to the TCR influences helper T cell function differently both in vitro 23 and in vivo with TCR-transgenic helper T cells 24, 25 . Helper T cells with strong pMHCII binding 'preferentially' emerge in the draining lymph nodes and persist locally as a unique compartment of antigen-specific memory T FH cells 14 . However, it remains unclear whether the distribution of TCRs with substantial pMHCII binding strength is a consequence of local lymphoid priming or whether intrinsic TCR signal strength causally directs the effector T FH developmental program.
To address those issues, it is important to connect the functional development of antigen-specific helper T cells with TCR binding strength and repertoire diversity. The I-E k -restricted helper T cell response of B10.BR mice to pigeon cytochrome c (PCC) is the only tractable protein vaccination model available at present with this capacity 26, 27 . Antigen-specific helper T cells can be detected with antibodies to expressed variable (V) regions such as V a 11 and V b 3, as well as pMHCII tetramers presenting the dominant peptide epitope. Responding pMHCII-specific helper T cells express a restricted TCR repertoire with demonstrable clonal diversity 26, 27 and a range of TCRbinding properties 28, 29 . In this model, antigen-specific effector helper T cells have many effector functions 30 and changes in TCR triggering associated with the response to antigen 31 . After vaccination with protein, intrinsic TCR affinity thresholds regulate clonal selection and the composition of pMHCII-specific clones in the local draining lymphoid tissues 28, 29 . Hence, it is critical to determine whether similar TCR affinity-based mechanisms exist for the regulation of the function of antigen-specific T FH cells.
Here we subcategorized the total antigen-specific helper T cell compartment into three subsets of CD44 hi ICOS hi effector helper T cells. All antigen-specific subsets expressed similar amounts of IL-2, IL-10, IFN-g and the transcription factor T-bet. Antigen-specific 'lymphoid' effector helper T cells expressing Blimp-1 (A003268) retained expression of L-selectin (CD62L) and CCR7, confining their effector activity to the T cell zones of responding lymph nodes. In contrast, most antigen-specific helper T cells that developed locally exited the lymph nodes as CD62L lo CCR7 lo 'emigrant' effector helper T cells. There were also many Bcl-6-expressing CXCR5 hi T FH cells that remained 'resident' in lymph nodes with the highest expression of IL-4, IL-21, PD-1 and unique expression of CD69 and OX40 in the B cell zones to regulate antigen-primed B cells. Naive antigen-specific helper T cells with TCR of higher affinity 'preferentially' skewed into the CXCR5 hi 'resident' T FH compartment. Increasing doses of agonist peptide over 3 d in vitro induced maximum IL-21 expression and lower Blimp-1 expression without affecting Bcl-6 expression. In the polyclonal model, TCRs with the strongest pMHCII binding and more restricted junctional diversity 'preferentially' skewed into the antigen-specific effector T FH compartment. Furthermore, vaccine adjuvants that promoted responders of higher affinity also induced the largest number of antigen-specific T FH cells in vivo. Thus, we demonstrate that antigen-specific mechanisms for 'programming' the differentiation of effector T FH cells in vivo are causally related to the strength of TCR binding and the diversity of the responding helper T cell population. Manipulating these mechanisms in vivo will underpin the formulation of the next generation of protein vaccines.
RESULTS

Three subsets of antigen-specific effector helper T cells
We immunized mice subcutaneously at the base of tail with whole protein antigen in the monophosphoryl lipid A-based adjuvant Ribi. Maximum accumulation of PCC-specific effector helper T cells in draining lymph nodes was reached by the end of the first week after subcutaneous vaccination of B10.BR mice with protein 26 . Using pMHCII binding (Fig. 1a) and upregulation of CD44 on V a 11 + V b 3 + helper T cells (Fig. 1b) , we separated PCC-specific helper T cells into three distinct subsets on the basis of their expression of CXCR5 and CD62L. Two CXCR5 lo subsets reached peak numbers by day 5 (Fig. 1c) and could be distinguished by their abundance of CD62L protein and mRNA (Fig. 1d) . CXCR5 expression was present in the third major subset of antigen-specific helper T cells that had lost CD62L expression and reached peak numbers by day 7. Quantitative evaluation of mRNA expression in vivo correlated well with protein expression for CD44, CD62L and CXCR5 (Fig. 1d) . Thus, after protein vaccination, CXCR5 hi T FH cells constitute only half of the antigen-specific helper T cells that accumulate in the draining lymph node.
Blimp-1-expressing 'lymphoid' effector helper T cells All three antigen-specific helper T cells had the qualities of effector cells in vivo by day 7. All subsets had higher in vivo surface expression of CD28 protein and mRNA (Fig. 2a) and ICOS protein and mRNA (Fig. 2b) . There was much higher expression of IL-2, IFN-g and IL-10 mRNA without in vitro restimulation (Fig. 2c) , which indicated similar effector cell potential for all subsets in vivo. The CD62L hi subset also retained expression of CCR7 similar to that of naive helper T cells (Fig. 2d) , which indicated a capacity for lymphoid recirculation and placement in the T cell zones, even during an active immune response. As for the transcriptional regulation of effector cell differentiation, all subsets had similarly higher expression of T-bet than that of naive helper T cells, but only the CD62L hi CXCR7 hi subset expressed Blimp-1 at this stage of the immune response (Fig. 2e) . On the basis of the cell surface phenotype, we refer to the Blimp-1-expressing subset as 'lymphoid' effector helper T cells.
Most helper T cells are 'emigrant' effector helper T cells Sphingosine 1-phosphate receptor agonists such as FTY720 and its chiral analog AAL-R (2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol) inhibit the migration of and promote the lymph node retention of lymphocytes 32, 33 . We found many more antigen-specific helper T cells in draining lymph nodes after 7 d of treatment with AAL-R than after treatment with vehicle only (Fig. 3a and Supplementary  Fig. 1 online) . There were no changes in the number of antigenspecific T FH cells, which indicated the 'resident' nature of this effector helper T cell compartment. The 'lymphoid' effector helper T cells also remained mostly unchanged, which suggests that this T zone-localized effector compartment delivers its function locally during this acute phase of the immune response. In contrast, there were over ten times more CD62L lo CCR7 lo CXCR5 lo effector helper T cells after AAL-R treatment (Fig. 3a) , which suggested that most of these effector helper T cells developed locally but exited the draining lymph node during this first week after priming. Furthermore, there were considerably fewer antigen-specific helper T cells in the spleen after AAL-R treatment, which could be accounted for mostly by the lower number of CD62L lo CXCR5 lo effector helper T cells than in untreated mice ( Supplementary Fig. 2 online) . Thus, we refer to this CD62L lo CXCR5 lo antigen-specific compartment as 'emigrant' effector helper T cells to emphasize their most distinguishing cellular attribute in vivo.
Bcl-6-expressing 'resident' effector T FH cells
In addition to CXCR5, the negative regulator of T cell activation PD-1 has been reported to be present on a germinal center subset of T FH cells 34 . We found that similar fractions of CD44 hi CD62L lo antigenspecific helper T cells and cells of the CXCR5 + T FH subset expressed PD-1 protein and mRNA (Fig. 3b) . Although all three populations of effector helper T cells expressed more PD-1 mRNA than did naive helper T cells, the effector T FH compartment had significantly higher expression than did the other two subsets. Cytokines IL-4 and IL-21, which are also associated with the generation and function of effector T FH cells [1] [2] [3] [4] , were expressed by all three effector helper T cell subsets, but the effector T FH compartment had significantly higher expression (Fig. 3c) . In contrast, high expression of CD69 (Fig. 3d) and OX40 ( Fig. 3e) 'assorted' uniquely into the effector T FH compartment. As for the transcriptional control of effector compartments, Bcl-6 was also uniquely expressed by the effector T FH compartment and was not present in the other two subsets at this stage of the acute response (Fig. 3f) . Therefore, higher expression of PD-1, IL-4 and IL-21 and unique expression of CD69, OX40 and Bcl-6 distinguish the 'resident' effector T FH compartment that is 'placed' in the B cell zones of lymph nodes to deliver these activities to antigen-primed B cells.
High-affinity precursors develop into 'resident' T FH cells
To begin to assess the involvement of TCR affinity in the regulation of effector T FH function, we used the 5C.C7 (higher affinity) and 2B4 (lower affinity) PCC-specific TCRab-transgenic helper T cell populations in adoptive-transfer experiments 22, 28 . We transferred small numbers of CD90.2-expressing transgenic cells into otherwise replete unmanipulated recipient mice, which allowed the emergence of endogenous CD90.1-expressing PCC-specific responses (Supplementary Fig. 3 online) . The frequency of recruited 5C.C7 helper T cells differed from that of the 2B4 cells with no indication of the differences in the dynamics of clonal expansion or contraction expected in these vaccination conditions 28, 29 . Nevertheless, a significantly larger fraction of high-affinity responders than low-affinity responders developed into CXCR5 + 'resident' T FH cells (Fig. 4a) . Even after 7 d of activation and effector cell differentiation in vivo, the differences in mean fluorescence intensity (MFI) for pMHCII tetramer binding correlated with the preimmune differences in TCR affinity for the helper T cell populations (Fig. 4b) . All subsets had equivalent expression of V a 11 (data not shown). With both transgenic populations together in a cotransfer experimental design, significantly more higher affinity 5C.C7 helper T cells than lower affinity 2B4 helper T cells developed into CXCR5 + 'resident' T FH cells (Fig. 4c) . These data show that monoclonal TCR-expressing helper T cells can develop into all three subsets, yet precursors with a high-affinity TCR 'preferentially' develop into CXCR5 + 'resident' T FH cells in vivo.
In the cotransfer experiment, we detected more binding of pMHCII in the effector T FH compartment than in the other effector compartments, consistent with the higher ratio of 5C.C7 helper T cells to 2B4 helper T cells in the T FH compartment. We obtained similar results using cytochalasin D (Fig. 4d) , which disrupts cytoskeletal activity needed for aggregation of TCRs at the cell surface. These results suggest that the greater intensity of pMHCII binding in the T FH compartment was due more to TCR repertoire differences than to physiological changes associated with effector cell differentiation in vivo. The endogenous PCC-specific response in this cotransfer experiment showed trends for pMHCII binding similar to those obtained with the transgenic helper T cells and also remained in the presence of cytochalasin D ( Supplementary Fig. 4 online). Consistent with those findings, adoptive transfer of 5C.C7 TCRb chaintransgenic helper T cells into unmanipulated mice followed by immunization with PCC also produced a CXCR5 + T FH compartment with the highest pMHCII tetramer binding of the three phenotypically defined helper T cell subsets that emerged ( Supplementary Fig. 5 online). These data collectively indicate a causal connection between the TCR affinity of antigen-specific precursors and their differentiation into various effector helper T cell compartments.
Greater TCR signal strength induces IL-21 in vitro
We next addressed the function of TCR signal strength with peptide stimulation of transgenic helper T cells in vitro. All doses of moth cytochrome c (MCC) agonist peptide induced maximum clonal expansion of naive 5C.C7 helper T cells, as assessed by the resultant abundance of b 2 -microglobulin mRNA after the use of various stimuli ( Supplementary Fig. 5a ). In contrast, expression of IL-21 mRNA required tenfold higher concentrations of MCC peptide, with 10 mM MCC inducing maximum amounts of IL-21 in vitro (Fig. 4e) . Furthermore, all peptide doses induced similar Bcl-6 expression, but Blimp-1 expression was inversely correlated with IL-21 induction. The lower affinity 2B4 clonotype induced less maximum clonal accumulation at all doses of MCC peptide ( Supplementary Fig. 6a online) but failed to induce substantial expression of IL-21 mRNA above the baseline expression detected in vitro (Fig. 4f) . Unlike the results obtained with 5C.C7 cells, expression of both Bcl-6 and Blimp-1 remained unchanged in 2B4 cells at all peptide doses tested (Fig. 4f) . We used the peptide MCC(102S) 22 to create a ligand of lower affinity for the 5C.C7 ab TCR and again found less total clonal expansion at all peptide concentrations in vitro ( Supplementary Fig. 6a ). In these conditions, we noted higher IL-21 expression only at the highest peptide concentration; this also correlated with higher Bcl-6 expression. However, in these conditions, Blimp-1 expression was much higher at all doses of peptide ( Supplementary Fig. 6b ). Thus, it is clear that maximum IL-21 expression can be induced by stronger TCR signals in vitro with an effect on the relative balance in the expression of Bcl-6 and Blimp-1, even in the absence of B cells.
'Resident' T FH cells have stronger pMHCII binding
Although adoptive transfer provides direct access to antigen-specific precursors, it was important to address this issue in B10.BR mice with a polyclonal TCR repertoire in which precursor frequencies are more physiologically relevant. We detected considerable differences in pMHCII binding intensity for the three antigen-specific effector helper T cell compartments (Fig. 5a) . All subsets expressed similar amounts of TCR, on the basis of V a 11 expression, but had progressively higher MFI values of pMHCII binding (Fig. 5b) . 'Resident' T FH cells had the greatest pMHCII binding intensity for each mouse tested. At all concentrations of pMHCII, the 'resident' T FH compartment bound significantly more pMHCII complex than did the 'lymphoid' or 'emigrant' effector helper T cell compartment (Fig. 5c and Supplementary Fig. 7 online) . Although the 'emigrant' effector helper T cells present at day 7 in draining lymph nodes represented a small fraction of this compartment ( Fig. 3a and Supplementary Fig. 2 ), the splenic 'effector' helper T cells present from this time point on are considered part of the emigrant subset and have also been shown to have less pMHCII binding 14 . At optimal concentrations of pMHCII, the 'resident' T FH compartment bound more pMHCII more quickly than did the other effector compartments, reaching the maximum tetramer binding detected for the CD62L hi subset in only 30 min ( Fig. 5d and Supplementary Fig. 8 online) . These trends in the polyclonal repertoire also indicate a skewing of antigen-specific precursors with stronger pMHCII binding of TCR into the 'resident' T FH compartment.
'Resident' T FH cells express a restricted TCR repertoire As found in the adoptive-transfer experiments, we suspected that differences in pMHCII binding in vivo reflected differences in the expressed TCR. To test our idea more directly in the polyclonal model, we sorted single antigen-specific helper T cells from each effector helper T subset for TCR repertoire analysis. There are eight canonical features in the complementarity-determining region (CDR3) of PCCspecific TCR receptors, which for the TCRa chain consists of glutamic acid and serine at positions 93 and 95, respectively, a CDR3 length of eight amino acids and J a 16, J a 17, J a 22 or J a 34, and for TCRb, asparagine at position 100 and alanine or glycine at position 102, a CDR3 length of nine amino acids and J b 1.2 or J b 2.5. The presence of six or more of these features defines clonal dominance in this polyclonal TCR repertoire 26, 27 . Most antigen-specific helper T cells in all functional subsets had six or more of these attributes (Fig. 6a) . However, consistent with the pMHCII binding, there was a progressive increase in the proportion of restricted TCR use for the CD62L hi CXCR5 lo 'lymphoid' , CD62L lo CXCR5 lo 'emigrant' and CD62L lo CXCR5 hi 'resident' effector helper T cell compartments. The differences in repertoire diversity were noticeable in the TCRa chain use of the lymphoid compartments ( Fig. 6b and Supplementary  Fig. 9 online) and with differences in the TCRb chains for all three effector subsets ( Fig. 6c and Supplementary Fig. 10 online) . The TCR use of T FH cells resembled that of only 36% of the 'emigrant' helper T cells and 17% of the 'lymphoid' helper T cells in this response ( Supplementary Fig. 11 online) . Thus, the 'resident' T FH subset of antigen-specific effector cells expressed TCRs with stronger pMHCII binding and a much more restricted repertoire.
Vaccine adjuvants affect T FH development in vivo
To further address the mechanism underlying functional 'programming' in vivo, we sought ways to alter the responder clonal composition in the polyclonal vaccine model. Published studies have shown that decreasing the antigen dose over a two-log range does not affect clonal composition in this model 28, 29 . Using a dose of protein that was tenfold higher or one-tenth as high, we found no effect on clonal expansion ( Supplementary Fig. 12a online) , overall pMHCII tetramer binding ( Supplementary Fig. 12b) or the proportion or number of antigen-specific T FH cells ( Supplementary Fig. 12c ). With these very different doses of antigen stimuli, we also detected similar numbers of antigen-specific helper T cells from all three subsets ( Supplementary Fig. 12d ), which indicated there was no effect on functional differentiation. for each subset (as described in Fig. 1d ). (a) Each filled symbol represents the number of the following 'preferred' CDR3 features known to be selected in the PCC response for a single cell: CDR3a, glutamic acid at a93, serine at a95, eight amino acids, Ja16, Ja17, Ja22 and Ja34; CDR3b, asparagine at b100, alanine or glycine at b102, nine amino acids, Jb1.2 and Jb2.5. Middle row: percent cells (± s.e.m.) with six or more 'preferred' features, expressing a restricted TCR of the dominant clonotype (among n ¼ number of single cells used in the analysis (bottom row); three individual mice). *, P r 0.05, and **, P r 0.01 (unpaired Student's t-test). Fig. 13a  online) . However, the helper T cells selected into this response had an overall greater pMHCII binding intensity than that of the total responding population obtained by vaccination with the agonist MCC peptide (Supplementary Fig. 13b ). These trends suggested the imposition of a higher selection threshold at the initiation of the immune response. In these conditions of more stringent clonal selection, there were significantly larger proportions of antigenspecific T FH cells with stronger pMHCII binding with MCC(102S) than with the agonist MCC peptide (Fig. 7a,b) .
Next we used the agonist MCC peptide consisting of amino acids 88-103 (MCC(88-103)) and the altered peptide MCC(102S) as immunogens to vaccinate B10.BR mice. Vaccination with MCC(102S) induced substantial clonal expansion but less than that obtained with the MCC agonist peptide (Supplementary
Different vaccine adjuvants alter the selection threshold and clonal composition of antigen-responsive helper T cells 29 . Aluminum hydroxide (alum) and incomplete Freund's adjuvant (IFA) allowed clonotypes of lower affinity to emerge and persist, whereas the oligodinucleotide CpG adjuvant promoted a high-affinity clonal composition similar to that obtained with the monophosphoryl lipid A-based adjuvant Ribi ( Supplementary Fig. 14a,b online) . Here, we noted a significantly smaller proportion of antigen-specific T FH cells (Fig. 7c) and fewer total antigen-specific T FH cells (Fig. 7d) when we used alum or IFA than when we used CpG or Ribi. The T FH composition of the responding population correlated with the different effects of these adjuvants on clonal expansion in vivo. With each adjuvant, the antigen-specific T FH cell subset expressed TCRs with the strongest pMHCII binding relative to that of the other two antigenspecific effector compartments (Fig. 7e) . These data further support the idea of a causal relationship between the strength of TCR signals delivered during clonal selection and the functional program subsequently adopted by the antigen-specific effector T FH cell compartment in vivo ( Supplementary Fig. 15 online) .
DISCUSSION
The capacity for lymphoid recirculation, regional 'placement' in lymphoid tissue and migratory activity can be used to categorize cells of the antigen-responsive effector helper T cell compartment. The CD62L hi 'lymphoid' effector helper T cells retain the ability to reenter lymph nodes but remain CCR7 hi with negligible exit from lymph nodes during the first week of priming. Hence, these cytokineproducing CD44 hi ICOS hi effector cells may provide additional cognate help for antigen-primed B cells already in the extrafollicular regions 2 . These specialized effectors could also maintain 35 or reestablish contact with pMHCII-expressing dendritic cells for their own survival and development 36 . Alternatively, this effector helper T subset may be needed to 'license' dendritic cells for help to CD8 T cells in crosspresentation functions or perhaps an extrafollicular function for helper T cells to promote isotype switching without somatic diversification 37 . As there are CD62L hi memory helper T cells with this cell surface phenotype 38 , it is plausible that this 'lymphoid' effector program may also give rise to a recirculating lymphoid 'central memory' helper T cell compartment.
CXCR5 hi effector helper T cells had all lost CCR7 expression, ensuring their 'placement' in the follicular B cell zones of lymphoid tissues 7, 8 . These cells had lost CD62L expression, which indicated that if they left the lymph node, reentry would be a rare event. The results obtained with AAL-R treatment 32, 33 strongly supported the idea of the 'resident' status of these follicular helper T cells 14 Fig. 5b ) from lymph nodes on day 7 after priming with PCC in alum, IFA or CpG. *, P r 0.05 (one-tail paired Student's t-test). Data are representative of at least three experiments.
The transcription factor T-bet is required for the differentiation of T helper type 1 cells 39 . In our study here, all subsets had equivalent expression of T-bet mRNA that would account for the presence of IFN-g in all effector compartments. However, the cognate delivery of IFN-g to different target cells would induce separate immune functions in vivo, such as immunoglobulin G2a isotype switching in antigen-primed B cells 12, 39 . Such a pattern would suggest the presence of T helper type 1-like cells in the broad class of effector T FH cells. The presence of IL-4 in the antigen-specific T FH compartment supports the same idea, with evidence of the presence of T helper type 2 cells as well in the T FH compartment. Published data indicate that T FH cells are able to produce IL-17 (ref. 40) . Such trends suggest that effector T FH cells have heterogeneous patterns of production of cytokines all known to be involved in the regulation of B cell immunity.
The larger amounts of transcriptional repressor Blimp-1 only in the 'lymphoid' effector compartment suggested different programs of development. Blimp-1 controls the plasma cell program of B cells 41, 42 and is involved in regulatory helper T cells 43 and T helper type 1 differentiation 44 . Bcl-6 is also involved in antigen-driven B cell development and is required for germinal center formation 45 . Notably, Bcl-6 is a direct target for Blimp-1 repression, and the mutual repression of these two factors is important for maintaining the separate B cell fates 44 . In the CD4 + compartment, Blimp-1-deficient helper T cells have higher Bcl-6 expression 46 . Thus, Blimp-1 and Bcl-6 may regulate mutually exclusive 'lymphoid' effector helper T cell and 'resident' effector T FH cell developmental programs in the response to vaccination with protein.
TCR recognition of pMHCII complexes on antigen-presenting cells defines the first main checkpoint in the development of antigenspecific helper T cells in vivo 2 . Most models favor the idea that TCR affinity 21, 22, 29, 47 or the strength and duration 48, 49 of the binding of pMHCII to antigen-specific helper T cells controls these initial recognition events. Unlike CD8 + cells, the helper T cell compartment requires continued 35 or multiple 36 contacts with antigen-presenting cells for maximum clonal expansion in vivo. These sequential cognate interactions provide opportunities for the antigen-specific helper T cells to deliver effector functions and receive new developmental programming signals at later phases of the immune response. The costimulatory context of pMHCII expression and the cytokines produced by the antigen-presenting cell and by the responding helper T cells can affect the differentiation of helper T cells. IL-21 is important in the costimulation of antigen-specific T FH differentiation 15, 16 . Hence, soluble and cell-associated microenvironmental factors also influence the differentiation of antigen-specific effector helper T cells during the acute phase of an immune response.
T FH cells represent a class of effector helper T cells responsible for the antigen-specific regulation of B cell immunity 1, 3, 4 . Published studies have further identified a function for IL-6 and STAT3 in the IL-21-dependent genetic program that initiates T FH development 15 . Notably, these studies have also demonstrated that expression of the ICOS ligand on B cells is needed to promote this specialized effector T FH compartment in vivo. Other studies have also indicated that ICOS expression on helper T cells is needed for the production of IL-4 and IL-21 but not for CXCR5 expression 37 . The costimulation of TCR signals has been identified as an important factor in IL-21 production, thereby promoting effector T FH development in vivo 16 . Our analyses here have added involvement of the strength of TCR signal itself in the early programming events involved in the development of antigenspecific T FH cells. It remains unclear whether the initial selection events between naive helper T cells and antigen-primed dendritic cells impose the critical selection events that affect the functional program. Alternatively, it may be the secondary encounter with pMHCIIexpressing antigen-primed B cells that is critical for the 'imprinting' of effector T FH function, as suggested before 17 .
Vaccine adjuvants affect clonal-selection mechanisms, changing the distribution of the 'preferred' TCR affinity for responding clonotypes and altering the clonal composition of the effector helper T cell compartment. Our studies here indicate that the initial strength of TCR binding also regulates the function of antigen-specific effector helper T cells. TCR with stronger pMHCII binding 'preferentially' drive antigen-specific precursors into the 'resident' effector T FH compartment with the ability to control B cell immunity. Thus, manipulation of the clonal selection in helper T cells and regulation of the balance of effector helper T cell differentiation will provide a powerful new strategy for the future design of protein vaccines. Flow cytometry. For population analysis, draining lymph nodes (inguinal and periaortic) were removed from immunized mice and were prepared and pelleted, then were resuspended in PBS with 5% (vol/vol) FCS and stained for flow cytometry at a density of 2.0 Â 10 8 cells per ml. For tetramer staining, cells were first stained for 2 h at 20 1C with the optimal concentration of pMHCII tetramer (240 nM, prepared as described 28 ). Where required, cytochalasin D was used at a final concentration of 50 mM (Sigma). Then, cells were incubated for 45 min at 4 1C with predetermined optimal concentrations of the following fluorophorelabeled (or biotin-labeled) monoclonal antibodies: fluorescein isothiocyanateconjugated anti-V a 11 (RR8.1) or anti-Thy-1.2 (53-2.1), phycoerythrin-conjugated anti-CD4 (L3T4), allophycocyanin-conjugated anti-CD44 (Pgp1) or anti-V b 3 (KJ25), indodicarbocyanine-phycoerythrin-conjugated anti-B220 (6B2) or anti-CD8 (53-6.7), and biotin-conjugated anti-CXCR5 (2G8) or anti-CD28 (37.51; all from BD Pharmingen); indodicarbocyanine-phycoerythrinconjugated anti-Thy-1.1 (HIS51), indotricarbocyanine-phycoerythrin-conjugated anti-CD62L (Mel14), indotricarbocyanine-allophycocyanin-conjugated or allophycocyanin-Alexa Fluor 750-conjugated anti-CD44 (IM7), and biotin-conjugated anti-CCR7 (4B12), anti-CD69 (H1.2F3), anti-PD-1 (J43), anti-ICOS (7E.17G9) or anti-OX40 (OX86; all from eBioscience); and indodicarbocyanine-phycoerythrin-conjugated anti-CD11b (M1/70.15) or anti-CD4 (L3T4), and Pacific blue-conjugated anti-B220 (6B2; all from Biolegend). Streptavidin-phycoerythrin (BD Pharmingen) or streptavidin-indotricarbocyanine-allophycocyanin (BD Pharmingen) was used as a second-step visualization reagent. Cells were washed, were resuspended in propidium iodide (2 mg/ml in 5% (vol/vol) FCS in PBS) for exclusion of dead cells and were analyzed with a FACSVantage SE (BD Biosciences) with CellQuest or FACSDiva software (BD Biosciences). Data were analyzed with FlowJo software (Tree Star). Profiles are presented as 5% probability contours with outliers.
Single-cell repertoire analysis. Single cells with the appropriate surface phenotype were sorted for repertoire analysis with a FACSVantage SE and It has been called to our attention that in a series of studies on the development of follicular helper T cells (T FH cells), the primers we used to amplify Bcl6 were specific for Bcl6b, not Bcl6. We have now traced back the results and have redone experiments that demonstrate that both Bcl6 and Bcl6b are modified in the same way and to a similar extent in antigen-specific and non-antigen-specific T FH cells induced both in vivo and in vitro.
In the original studies we inadvertently mixed up primers specific for Bcl6b (but not for Bcl6) with those specific for Bcl6. After closer inspection, we found that this error was made when the wrong set of primers was ordered and labeled "Bcl6 #2" in our laboratory but the primers were in fact specific for Bcl6b. We used both sets of primers in the original studies of gene expression on antigen-specific T FH cells analyzed immediately after isolation (Fig. 3f in Nat. Immunol. 10, 375-384 (2009), and Addendum Fig. 1) . Hence, the expression of both Bcl6 and Bcl6b seemed to be three-to fourfold higher in pigeon cytochrome c (PCC)-specific T FH cells than in naive CD4 + helper T cells.
As these genes are structurally related, we were concerned that the primers for Bcl6b may have sufficiently cross-reacted with Bcl6 and perhaps amplified the latter gene in T cells. Thus, we sorted antigen-specific T FH cells immediately after isolation and amplified random hexamer-primed cDNA with both sets of primers (Addendum Fig. 2 ). Both gene products were amplified and produced PCR products of different sizes (the predicted sizes for the different gene products). We then sequenced these products to demonstrate they belonged to the different genes as presented. Thus, both primers amplified the expected PCR products in both naive helper T cells and antigen-specific T FH cells.
To explore this issue further, we sorted non-antigen-specific T FH cells on the basis of cell surface phenotype and amplified DNA from these cells by RT-PCR without further treatment (Addendum Fig. 3) . These experiments also showed that both Bcl6 and Bcl6b had similar basal expression in naive helper T cells and a similar change of expression in CXCR5 + T FH cells.
In our more recent study on antigen presentation by plasma cells (Nat. Immunol. 11, 1110-1118 (2010)), we reported that plasma cells negatively regulate the T FH program in vitro and in vivo. Our conclusions were based on expression of the genes encoding interleukin 21 (IL-21) and Bcl-6, as measured by reverse transcription and quantitative PCR. The original primer mix-up continued in the early phase of these studies. However, the error was sporadic and these more recent studies reported on Bcl6 and not Bcl6b, as outlined below (Addendum Table 1 ).
Hence, we concluded that antigen presentation by plasma cells inhibits the expression of mRNA for IL-21 and Bcl-6 by in vivo-derived, endogenous, antigen-specific T FH cells (Fig. 5d, second panel, in Nat. Immunol. 11, 1110-1118 (2010)). Furthermore, the adoptive transfer of antigen-pulsed plasma cells significantly inhibited the expression of mRNA for both IL-21 and Bcl-6 on antigen-specific T FH cells (Fig. 7i, in Nat. Immunol. 11, 1110-1118 (2010)) without affecting the expression of mRNA for IL-4 or the transcription factor GATA-3 in vivo. Therefore, this provided evidence of antigen-specific negative regulation of the T FH program by plasma cells in vivo.
We have also repeated the in vitro experiments using dendritic cells (DCs) or plasma cells as antigen-presenting cells to evaluate the expression of Bcl6 and Bcl6b after in vitro induction of T FH cell activity ( Addendum Fig. 4) . These studies demonstrated equivalent induction of both Bcl6 and Bcl6b in vitro with DCs as antigen-presenting cells and naive helper T cells with transgenic expression of the 5C.C7 ab T cell antigen receptor (abTCR) as antigen-specific helper T cells in these cultures. Consistent with the overall conclusions of our earlier study (Nat. Immunol. 11, 1110−1118 (2010)) plasma cells with antigen did not induce Bcl6 or Bcl6b in 5C.C7 abTCR-transgenic helper T cells in vitro.
We did these new experiments without secondary in vitro transcription or specific synthesis of target cDNA and preamplification by PCR to evaluate the extent of signal to be expected for Bcl6 after in vitro activation of T FH cells. The tenfold induction of both Bcl6 and Bcl6b in these studies is more in line with the expected results and the results of other studies using standard culturing conditions to induce T FH cell activity. These data are also more in line with the expression of Bcl6 and Bcl6b on antigen-specific T FH cells derived in vivo we have reported in all our studies. We believe that the starting cell population, in particular the primary culture stimulus, atypical secondary culture conditions and secondary amplification of the assay all contributed to the more enhanced signals we reported before for Bcl6b (Fig. 5b,c in Nat. Immunol. 11, 1110−1118 (2010)).
In conclusion, we mixed up primers for Bcl6 amplification and in parts of our published work inadvertently reported on Bcl6b, not Bcl6. Bcl6b is a distinct gene but remains a structurally and functionally related member of the Bcl6 gene family. We have now been able to revisit this issue and have demonstrated that both Bcl6 and Bcl6b seemed to be coexpressed to a similar extent in naive helper T cells. Both gene products were similarly enhanced in T FH cells that emerged in vivo or were derived in vitro. Furthermore, both genes seemed to be inhibited similarly by antigen presentation by plasma cells. Hence, we believe that this addendum will rectify the mistake made in the initial studies and clarify the coexpression of Bcl6 and Bcl6b in antigen-specific T FH cells. Induction of Bcl6 or Bcl6b in T FH cells selectively by dC antigen presentation and inhibition of Bcl6 by PC antigen presentation, assessed by two rounds of in vitro amplification (IVT) of Rna with a Messengeramp II aRna amplification kit (ambion), similar to what is done before microarray analysis, followed by the generation of cdna from 10 mg amplified Rna as the starting material for SYBR Green-based quantitative PCR analysis; by specific target amplification (STa) with specific primers to generate cdna, followed by 14 cycles of PCR preamplification and dilution of the product 1:5 for use as the starting material for SYBR Green-based quantitative PCR analysis; or the melting curve (T m ) peak signal after SYBR Green-based quantitative PCR analysis. Addendum Figure 1 Upregulation of both Bcl6 
